Literature DB >> 8970385

Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia.

H Tanaka1, S Honma, S Abe, H Tamura.   

Abstract

To elucidate the immunopathologic mechanisms of Mycoplasma pneumonia, the effects of interleukin-2 (IL-2) and cyclosporin A (CYA) on Mycoplasma pneumonia in mice were investigated. Mice were intranasally inoculated with Mycoplasma pulmonis (M. pul) and treated with IL-2, CYA, or minocycline (MINO) every day between Days 3 and 9. They were killed at Days 7, 14, or 21 after the inoculation. Cell-mediated immunity (CMI) of the host was assessed by delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC). Peribronchial and perivascular lymphocyte cuffing and the accumulation of macrophages at the ends of bronchioles were exacerbated (p < 0.05) in IL-2-treated mice at Day 14 and reduced (p < 0.05) in CYA-treated mice at Day 7. Although the DTH responses to SRBC of saline-inoculated, IL-2-treated mice were increased at Days 7 (p < 0.01) and 14 (p < 0.05), those of M. pul-inoculated, IL-2-treated mice at Day 7 could not recover to the control level. The CMI levels of M. pul-inoculated, CYA-treated mice were decreased at Days 7, 14 (p < 0.05), and 21 (p < 0.01). Mycoplasma organisms in the lung showed the greatest decrease (p < 0.05) in MINO- and IL-2-treated mice, but increased at Day 21 (p < 0.05) in mice treated with IL-2 alone. These results suggest that the pathologic features of Mycoplasma pneumonia could be modified by the degree of host CMI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970385     DOI: 10.1164/ajrccm.154.6.8970385

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection.

Authors:  M Narita; H Tanaka; S Yamada; S Abe; T Ariga; Y Sakiyama
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon.

Authors:  M Narita; H Tanaka; S Abe; S Yamada; M Kubota; T Togashi
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

3.  Mycoplasma pneumoniae pneumonia in children.

Authors:  You-Sook Youn; Kyung-Yil Lee
Journal:  Korean J Pediatr       Date:  2012-02-14

Review 4.  A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis.

Authors:  Kyung-Yil Lee
Journal:  Infect Chemother       Date:  2015-03-30

Review 5.  Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.

Authors:  Takeshi Saraya; Daisuke Kurai; Kazuhide Nakagaki; Yoshiko Sasaki; Shoichi Niwa; Hiroyuki Tsukagoshi; Hiroki Nunokawa; Kosuke Ohkuma; Naoki Tsujimoto; Susumu Hirao; Hiroo Wada; Haruyuki Ishii; Koh Nakata; Hirokazu Kimura; Kunihisa Kozawa; Hajime Takizawa; Hajime Goto
Journal:  Front Microbiol       Date:  2014-08-11       Impact factor: 5.640

Review 6.  Correlation between Radiological and Pathological Findings in Patients with Mycoplasma pneumoniae Pneumonia.

Authors:  Hiroshi Tanaka
Journal:  Front Microbiol       Date:  2016-05-11       Impact factor: 5.640

7.  The Correlation between Chest X-ray Scores and the Clinical Findings in Children and Adults with Mycoplasma pneumoniae Pneumonia.

Authors:  Takeshi Saraya; Takayasu Watanabe; Yayoi Tsukahara; Kosuke Ohkuma; Haruyuki Ishii; Hirokazu Kimura; Kunimasa Yan; Hajime Goto; Hajime Takizawa
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

Review 8.  Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy.

Authors:  Kyung-Yil Lee
Journal:  Int J Mol Sci       Date:  2017-02-11       Impact factor: 5.923

9.  Fatal Mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl.

Authors:  Florian Daxboeck; Bernhard Eisl; Christofer Burghuber; Mazda Memarsadeghi; Ojan Assadian; Gerold Stanek
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.